Latest Content

A structured exercise program may reduce cognitive decline, often referred to as “chemo brain,” in patients receiving chemotherapy for the first time.

Dr. Ajay K. Nooka, highlights how the evolution of therapy has moved the goalposts from simply achieving remission to pursuing a measurable cure.

Dr. Sandeep Kunwar explained that getting drugs into the brain is a major hurdle for glioblastoma, as the blood-brain barrier blocks most treatments.

After losing her eyelashes during chemotherapy, a two-time cancer survivor reflects on how their return reshaped her appreciation for a small but meaningful part of daily life.

An expert explains how immunotherapy, targeted therapy and tumor testing are expanding treatment options for patients with gynecologic cancers.

Preliminary INVINCIBLE-4 study data shows INT230-6 plus standard care may increase pathological complete response rates and improve patient safety.

Dr. Matthew Galsky discusses the background of the KEYNOTE-B15 study, the key results and what these findings could mean for patients.

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves survival in platinum-resistant ovarian cancer.

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care.

Only about 0.01% of biologic drugs reach glioblastoma tumors, but convection-enhanced delivery bypasses the barrier to deliver therapy directly to the brain.

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

During Kidney Cancer Awareness Month, Dr. Eric Singer shares warning signs, risk factors and when younger adults should speak with a doctor about kidney health.